Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is Meridian Bioscience, Inc. (VIVO) A Good Stock To Buy?

Page 1 of 2

There are several ways to beat the market, and investing in small cap stocks has historically been one of them. We like to improve the odds of beating the market further by examining what famous hedge fund operators such as Carl Icahn and George Soros think. Those hedge fund operators make billions of dollars each year by hiring the best and the brightest to do research on stocks, including small cap stocks that big brokerage houses simply don’t cover. Because of Carl Icahn and other successful funds’ exemplary historical records, we pay attention to their small cap picks. In this article, we use hedge fund filing data to analyze Meridian Bioscience, Inc. (NASDAQ:VIVO) .

Meridian Bioscience, Inc. (NASDAQ:VIVO) shareholders have witnessed a decrease in hedge fund interest recently. 16 hedge funds that we track were long the stock on September 30. There were 19 hedge funds in our database with VIVO positions at the end of the previous quarter. The level and the change in hedge fund popularity aren’t the only variables you need to analyze to decipher hedge funds’ perspectives. A stock may witness a boost in popularity but it may still be less popular than similarly priced stocks. That’s why at the end of this article we will examine companies such as First Commonwealth Financial (NYSE:FCF), Greenbrier Companies Inc (NYSE:GBX), and Innophos Holdings, Inc. (NASDAQ:IPHS) to gather more data points.

Follow Vical Inc (NASDAQ:VICL)
Trade (NASDAQ:VICL) Now!

At Insider Monkey, we’ve developed an investment strategy that has delivered market-beating returns over the past 12 months. Our strategy identifies the 100 best-performing funds of the previous quarter from among the collection of 700+ successful funds that we track in our database, which we accomplish using our returns methodology. We then study the portfolios of those 100 funds using the latest 13F data to uncover the 30 most popular mid-cap stocks (market caps of between $1 billion and $10 billion) among them to hold until the next filing period. This strategy delivered 18% gains over the past 12 months, more than doubling the 8% returns enjoyed by the S&P 500 ETFs.

type, sugar, blood, tester, finger, equipment, lancet, drop, photograph, glucometer, test, 2, medical, glaucometer, diabetes, glucose, monitor

Robyn Mackenzie/Shutterstock.com

Hedge fund activity in Meridian Bioscience, Inc. (NASDAQ:VIVO)

Heading into the fourth quarter of 2016, a total of 16 of the hedge funds tracked by Insider Monkey held long positions in this stock, a 16% drop from one quarter earlier. By comparison, 14 hedge funds held shares or bullish call options in VIVO heading into this year, so smart money ownership is still up for the year. So, let’s check out which hedge funds were among the top holders of the stock and which hedge funds were making big moves.
VIVO
When looking at the institutional investors followed by Insider Monkey, Jim Simons’ Renaissance Technologies has the biggest position in Meridian Bioscience, Inc. (NASDAQ:VIVO), worth close to $36.9 million. On Renaissance Technologies’ heels is Joel Greenblatt of Gotham Asset Management, with a $4.8 million position. Remaining hedge funds and institutional investors with similar optimism include Ken Griffin’s Citadel Investment Group, Mario Gabelli’s GAMCO Investors, and Richard S. Meisenberg’s ACK Asset Management. We should note that none of these hedge funds are among our list of the 100 best performing hedge funds which is based on the performance of their 13F long positions in non-microcap stocks.

Page 1 of 2